Havrix

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

CirrhosisVaccineVaccination

75 competitors in Cirrhosis

#DrugCompanyPhaseTrials

1

Sovaldi

Gilead

Approved

52

Cymbalta

Jazz Pharmaceuticals

Approved

13

Aldactone

Pfizer

Approved

14

Jardiance

Boehringer Ingelheim

Approved

25

Januvia

ZZydus Therapeutics Inc.

Approved

26

Bridion

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

17

Nexium

DDexcel Pharma Technologies Ltd.

Approved

18

Amoxil

GGlobal Antibiotics Research and Development Partnership

Approved

19

Bumex

VValidus Pharmaceuticals

Phase 3

110

Crestor

AstraZeneca

Phase 2

2Show 40 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Immunogenicity12 trials

Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age

Completed·GSK·Phase 3·NCT01978093·600 enrolled

Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age

Completed·GSK·Phase 2·NCT00578175·1,851 enrolled

Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age

Completed·GSK·Phase 2·NCT00861744·1,259 enrolled

Show 9 more trials

A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years

Completed·Pfizer·Phase 3·NCT01830855·3,596 enrolled

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life

Completed·GSK·Phase 3·NCT01681992·4,538 enrolled

Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents

Completed·GSK·Phase 2·NCT02212457·1,063 enrolled

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age

Completed·GSK·Phase 3·NCT02184572·1,742 enrolled

Immunogenicity, Antibody Persistence and Safety of GSK Biologicals' DTPa (INFANRIX) and dTpa (BOOSTRIX) Vaccines.

Terminated·GSK·Phase 4·NCT00544271·720 enrolled

Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age

Completed·GSK·Phase 3·NCT01702428·5,016 enrolled

Immunogenicity and Safety Study of Fluarix™ Vaccine in Children Who Have Previously Been Vaccinated With Pandemrix™

Completed·GSK·Phase 4·NCT01196026·162 enrolled

Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up Schedule

Completed·GSK·Phase 2·NCT00513409·163 enrolled

Pilot Study of the Immunogenicity, Reactogenicity and Tolerability of Two Schedules of a 4CmenB Vaccine in Adolescents and Young Adults

Completed·CCanadian Immunization Research Network·Phase 4·NCT02583412·120 enrolled

Hepatitis9 trials

Immunogenicity and Persistence of GlaxoSmithKline (GSK) Biologicals' Havrix® in Healthy Adult Subjects Vaccinated at Infancy Under the Hepatitis A Universal Mass Vaccination (UMV) Program in Israel

Withdrawn·GSK·Phase 4·NCT03183492

Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc

Completed·GSK·Phase 4·NCT00289731·596 enrolled

Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine Injected According to a 0, 12-month Schedule

Completed·GSK·Phase 4·NCT00291876·135 enrolled

Show 6 more trials

Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children

Completed·GSK·Phase 3·NCT00197015·1,474 enrolled

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine (Cervarix™) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) in Healthy Female Adolescents Aged 9-14 Years

Withdrawn·GSK·Phase 3·NCT02082639

Safety and Immunogenicity of a Paediatric Dose of Virosomal Hepatitis A Vaccine

Completed·CCrucell Holland BV·Phase 2·NCT01405677·308 enrolled

Study to Show That the Combined Hepatitis A and B Vaccine is Non-inferior to Monovalent Vaccines in Adults

Completed·GSK·Phase 4·NCT00603252·213 enrolled

Safety, Immunogenicity, and Immune Persistence Study of an Inactivated Hepatitis A Vaccine

Completed·Sinovac Biotech Co., Ltd·Phase 4·NCT00534885·400 enrolled

Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine, Injected According to 0, 6-month Schedule

Completed·GSK·Phase 4·NCT00289757·78 enrolled

Influenza3 trials

A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in Children

Completed·GSK·Phase 3·NCT01218308·5,220 enrolled

A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of GSK Biologicals' Influenza Vaccine in Children

Completed·GSK·Phase 3·NCT01379937·520 enrolled

An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children

Completed·GSK·Phase 3·NCT01439360·12,046 enrolled

Memory2 trials

Evaluation of Immune Memory to Twinrix or Comparator by Challenge Dose Administration 4 Years After Primary Vaccination

Completed·GSK·Phase 4·NCT00684671·506 enrolled

Antibody Persistence & Immune Memory in Healthy Adults Previously Vaccinated With Twinrix Adult

Completed·GSK·Phase 4·NCT01000324·44 enrolled

Herpes Simplex1 trial

Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old

Completed·GSK·Phase 3·NCT00224484·5,960 enrolled

12 more indications

Cirrhosis1 trial

Efficacy and Durability of Hepatitis A Vaccination in Patients With Advanced Fibrosis and Cirrhosis

Recruiting·MMahidol University·Phase 4·NCT06277882·50 enrolled

Adult1 trial

Long-term Persistence Study in Healthy Adults Previously Vaccinated With Twinrix Adult

Completed·GSK·Phase 4·NCT01037114·50 enrolled

Japanese encephalitis1 trial

Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440

Completed·VValneva Austria GmbH·Phase 3·NCT00596271·192 enrolled

Papilloma1 trial

Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine

Completed·GSK·Phase 3·NCT00316706·1,245 enrolled

Diphtheria1 trial

Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months

Completed·GSK·Phase 3·NCT00197236·468 enrolled

Plasmodium Falciparum1 trial

Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT03917654·1,301 enrolled

Bone Marrow Transplant1 trial

Patient-donor Vaccination in the Context of Allogeneic Bone Marrow Transplant With Post-transplant Cyclophosphamide

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT01282216·120 enrolled

Immune-mediated Diseases1 trial

Safety and Immunogenicity of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adults With Chronic Immune-Mediated Diseases

Terminated·CClover Biopharmaceuticals AUS Pty·Phase 3·NCT05012787·1 enrolled

Acute otitis media1 trial

COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine

Completed·GSK·Phase 3·NCT00466947·23,802 enrolled

Vaccine1 trial

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Recruiting·Sanofi·Phase 3·NCT06824194·2,320 enrolled

Children1 trial

Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate Vaccine

Completed·GSK·Phase 3·NCT00624819·524 enrolled

Vaccination1 trial

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Active, not recruiting·Sanofi·Phase 3·NCT06824181·580 enrolled

Details

Drug Info

Related News